Cargando…
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
Immunotherapy is a promising strategy for the treatment of Alzheimer’s disease (AD). Antibodies directed against Amyloid Beta (Aβ) are able to successfully clear plaques and reverse cognitive deficits in mouse models. Excitement towards this approach has been tempered by high profile failures in the...
Autores principales: | Fuller, James P., Stavenhagen, Jeffrey B., Christensen, Søren, Kartberg, Fredrik, Glennie, Martin J., Teeling, Jessica L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612324/ https://www.ncbi.nlm.nih.gov/pubmed/26433971 http://dx.doi.org/10.1007/s00401-015-1484-2 |
Ejemplares similares
-
Antibody-mediated clearance of tau in primary mouse microglial cultures requires Fcγ-receptor binding and functional lysosomes
por: Andersson, Christian Rungsted, et al.
Publicado: (2019) -
Is abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
por: Moreth, Jens, et al.
Publicado: (2013) -
Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015) -
New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease
por: Fuller, James P., et al.
Publicado: (2014) -
Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau
por: Rosenqvist, Nina, et al.
Publicado: (2018)